360iResearch Logo
Global Head & Neck Cancer Drugs Market
Report Code: MRR-CF423BF | Publishing Date: May 2020 | Number of Pages: 142
Global Head & Neck Cancer Drugs Market | Market Research Report | Cumulative Impact of COVID-19

Market Segmentation & Coverage:

The research report categorizes the Head & Neck Cancer Drugs Market to forecast the revenues and analyze the trends in each of the following segments:

On the basis of Drug Class, the Head & Neck Cancer Drugs Market is studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.

On the basis of Product, the Head & Neck Cancer Drugs Market is studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate).

On the basis of End User, the Head & Neck Cancer Drugs Market is studied across Cancer Research Institutes, Clinics, and Hospitals.

On the basis of Geography, the Head & Neck Cancer Drugs Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The Head & Neck Cancer Drugs Market is highly competitive and characterized by the presence of a large number of international and regional players in the market. The market has witnessed increasing competition between vendors based on the pricing model, technology differentiation, brand name, quality of service, price differentiation, and technical expertise.

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Head & Neck Cancer Drugs Market including AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Eli Lilly and Company Limited, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer Inc., Roche Holding AG, Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.

Scope of the Report:

AttributeDetails
Base Year for Estimation2019
Historical Period2017 - 2018
Estimation Period2020 - 2021
Forecast Year2025
Market RepresentationRevenue in USD Million
Report CoverageRevenue Forecast, Company Share, Competitive Landscape, and Industry Trends.
Customization ScopeIf you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization. We offer 20% free customization which is equivalent to 5 analysts working days.

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of the Head & Neck Cancer Drugs Market. Moreover, the study highlights current market trends and provides forecast. We also have highlighted future trends in the Head & Neck Cancer Drugs Market that will impact the demand during the forecast period. Moreover, the competitive analysis of the Head & Neck Cancer Drugs Market brings an insight on the company usability profiles of the leading players. Additionally, the analysis highlights business overview, strategy, and SWOT analysis of the key companies in the market.

Reasons to Buy:

The Head & Neck Cancer Drugs Market research study reveals hidden insights and dynamic, which in turn helps the players in the ecosystem take better strategic decisions. The firms looking for purchasing the Head & Neck Cancer Drugs Market research report could look for following prospects on their way to better understand the market that can aid further decision making and possibly identify the best opportunities to exploit.

  • Evaluate the qualitative and quantitative aspects of the report and analyze the Head & Neck Cancer Drugs Market penetration with respect to industries and geographies.
  • Evaluates the key vendors and deeply analyze competitive landscape, revenue pockets, market trends, growth prospects, pain points, drivers, restraints, challenges and opportunities of the Head & Neck Cancer Drugs Market.
  • Evaluate the key vendors in the Head & Neck Cancer Drugs Market in terms of products satisfaction and business strategy. This helps identify consumer preferences and understand its current position in 360iResearch FPNV Positioning Matrix.
  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & Coverage
    3. Years Considered for the Study
    4. Currency & Pricing
    5. Language
    6. Stakeholders
  2. Research & Forecasting
    1. Research Methodology
    2. Forecasting Methodology
  3. Executive Summary
    1. Market Outlook
    2. Geography Outlook
    3. Competitor Outlook
  4. Market Overview
    1. Introduction
    2. Head & Neck Cancer Drugs Market, By Geography
  5. Market Dynamics
    1. Introduction
    2. Drivers
    3. Restraints
    4. Opportunities
    5. Challenges
  6. Industry Trends
    1. Porters Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    2. Cumulative Impact of COVID-19
    3. Client Customizations
  7. Head & Neck Cancer Drugs Market, By Drug Class
    1. Introduction
    2. Chemotherapy
    3. Immunotherapy
    4. Radiation therapy
    5. Surgery
    6. Targeted Therapy
  8. Head & Neck Cancer Drugs Market, By Product
    1. Introduction
    2. Bleomycin
    3. Cetuximab
    4. Docetaxel
    5. Erbitux (Cetuximab)
    6. Hydrea (Hydroxyurea)
    7. Hydroxyurea
    8. Keytruda (Pembrolizumab)
    9. Methotrexate
    10. Nivolumab
    11. Opdivo (Nivolumab)
    12. Pembrolizumab
    13. Taxotere (Docetaxel)
    14. Trexall (Methotrexate)
  9. Head & Neck Cancer Drugs Market, By End User
    1. Introduction
    2. Cancer Research Institutes
    3. Clinics
    4. Hospitals
  10. Head & Neck Cancer Drugs Market, By Americas
    1. Introduction
    2. Argentina
    3. Brazil
    4. Canada
    5. Mexico
    6. United States
  11. Head & Neck Cancer Drugs Market, By Asia-Pacific
    1. Introduction
    2. Australia
    3. China
    4. India
    5. Indonesia
    6. Japan
    7. Malaysia
    8. Philippines
    9. South Korea
    10. Thailand
  12. Head & Neck Cancer Drugs Market, By Europe, Middle East & Africa
    1. Introduction
    2. France
    3. Germany
    4. Italy
    5. Netherlands
    6. Qatar
    7. Russia
    8. Saudi Arabia
    9. South Africa
    10. Spain
    11. United Arab Emirates
    12. United Kingdom
  13. Competitive Landscape
    1. FPNV Positioning Matrix
    2. Market Vendor Ranking Analysis
    3. Competitive Scenario
      1. Merger & Acquisition
      2. Agreement, Collaboration & Partnership
      3. New Product Launch & Enhancement
      4. Investment & Funding
  14. Company Usability Profiles
    1. AstraZeneca Plc.
    2. Bristol-Myers Squibb Company
    3. Celgene Corporation
    4. Eli Lilly and Company
    5. Eli Lilly and Company Limited
    6. F. Hoffmann-La Roche Ltd.
    7. Fresenius Medical Care AG & Co. KGaA
    8. Johnson & Johnson
    9. Merck & Co., Inc.
    10. Novartis
    11. Pfizer Inc.
    12. Roche Holding AG
    13. Sanofi
    14. Sun Pharmaceutical Industries Ltd.
    15. Teva Pharmaceutical Industries Limited
  15. Appendix
    1. Discussion Guide
    2. Edition Details
    3. License Details
    4. Pricing Details

List of Tables

  1. GLOBAL HEAD & NECK CANCER DRUGS MARKET: SEGMENTATION & COVERAGE
  2. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY GEOGRAPHY, 2017-2025 (USD MILLION)
  24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  28. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  29. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  30. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  31. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  32. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  33. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  34. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  35. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  36. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  37. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  38. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  39. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  40. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  41. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  42. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  43. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  44. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  45. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  46. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  47. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  48. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  49. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  50. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  51. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  52. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  53. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  54. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  55. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  56. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  57. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  58. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  59. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  60. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  61. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  62. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  63. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  64. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  65. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  66. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  67. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  68. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  69. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  70. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  71. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  72. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  73. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  74. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  75. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  76. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  77. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  78. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  79. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  80. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  81. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  82. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  83. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  84. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  85. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  86. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  87. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  88. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  89. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  90. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  91. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  92. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  93. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  94. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  95. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  96. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  97. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  98. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  99. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  100. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  101. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  102. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  103. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  104. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  105. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  106. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  107. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  108. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  109. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  110. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  111. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  112. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  113. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  114. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  115. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  116. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  117. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  118. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  119. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  120. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  121. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  122. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  123. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  124. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  125. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  126. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  127. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  128. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  129. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  130. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  131. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  132. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  133. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  134. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  135. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  136. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  137. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  138. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  139. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  140. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
  141. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2017-2025 (USD MILLION)
  142. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)
  143. GLOBAL HEAD & NECK CANCER DRUGS MARKET: RANKING
  144. GLOBAL HEAD & NECK CANCER DRUGS MARKET: BUSINESS STRATEGY
  145. GLOBAL HEAD & NECK CANCER DRUGS MARKET: PRODUCT SATISFACTION
  146. GLOBAL HEAD & NECK CANCER DRUGS MARKET: MERGER & ACQUISITION
  147. GLOBAL HEAD & NECK CANCER DRUGS MARKET: AGREEMENT, COLLABORATION & PARTNERSHIP
  148. GLOBAL HEAD & NECK CANCER DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  149. GLOBAL HEAD & NECK CANCER DRUGS MARKET: INVESTMENT & FUNDING
  150. null
  151. null
  152. null
  153. null
  154. null
  155. null
  156. null
  157. null
  158. null
  159. null
  160. null
  161. null
  162. null
  163. null
  164. null
  165. GLOBAL HEAD & NECK CANCER DRUGS MARKET: EDITION DETAILS
  166. GLOBAL HEAD & NECK CANCER DRUGS MARKET: LICENSE DETAILS
  167. GLOBAL HEAD & NECK CANCER DRUGS MARKET: PRICING DETAILS

List of Figures

  1. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2019 (USD MILLION)
  2. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY TYPE
  3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  6. GLOBAL HEAD & NECK CANCER DRUGS MARKET: MARKET DYNAMICS
  7. GLOBAL HEAD & NECK CANCER DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
  9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 (USD MILLION)
  10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2019 VS 2025 (USD MILLION)
  16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2025 (USD MILLION)
  17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2019 VS 2025 (USD MILLION)
  31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025 (USD MILLION)
  32. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  33. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  34. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  35. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  36. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  37. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  38. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  39. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  40. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  41. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  42. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  43. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  44. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  45. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  46. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  47. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  48. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  49. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  50. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  51. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  52. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  53. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  54. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  55. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  56. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  57. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  58. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  59. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  60. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  61. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  62. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
  63. GLOBAL HEAD & NECK CANCER DRUGS MARKET: FPNV POSITIONING MATRIX
  1. AstraZeneca Plc.
  2. Bristol-Myers Squibb Company
  3. Celgene Corporation
  4. Eli Lilly and Company
  5. Eli Lilly and Company Limited
  6. F. Hoffmann-La Roche Ltd.
  7. Fresenius Medical Care AG & Co. KGaA
  8. Johnson & Johnson
  9. Merck & Co., Inc.
  10. Novartis
  11. Pfizer Inc.
  12. Roche Holding AG
  13. Sanofi
  14. Sun Pharmaceutical Industries Ltd.
  15. Teva Pharmaceutical Industries Limited
Global Head & Neck Cancer Drugs Market
Report Code
MRR-CF423BF
Publication Date
May 2020
Number of Pages
142
Delivery Time
48 Hours
Available Formats

SELECT LICENSE TYPE

ENTERPRISE USER LICENSE $7949
CORPORATE USER LICENSE $6449
SINGLE USER LICENSE $4949